When was Spear Bio founded?

Spear Bio was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Spear Bio located?

Spear Bio is headquartered in Boston, United States.

Who is the current CEO of Spear Bio?

Feng Xuan of Spear Bio. They have also founded 1 company.

How many employees does Spear Bio have?

As of Feb 28, 2026, the latest employee count at Spear Bio is 48.

Is Spear Bio a funded company?

Spear Bio is a funded company, having raised a total of $49M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 14, 2021.

When was the latest funding round of Spear Bio?

Spear Bio's latest funding was a $***** Series A round on Jul 23, 2024, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $604M in funding in 2026 to date.

Where does Spear Bio rank among its competitors?

Spear Bio ranks 1st amongst 86 active competitors, of which 14 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was ProAxsis, which secured $299K in Jul, 2025.

Who are the top competitors of Spear Bio?

Spear Bio's top competitors include SurModics, Olink and Accellix. Among them, ProAxsis secured the most recent funding round in July, 2025.

Spear Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers. It offers TNAB-sure SARS-CoV-2 neutralizing antibody test kits for detecting antibodies in small samples. It also, offer a reagent-based platform for ultrasensitive protein detection in small sample volumes, with applications in research and diagnostics.

Key Metrics

Founded Year

2021

Location

Boston, United States

Stage

Series A

Total Funding

$49M in 4 rounds

Latest Funding Round

Series A, Jul 23, 2024, $*****

Investors

CDH & 6 more

Ranked

1^st among 86 active competitors

Employee Count

48 as on Feb 28, 2026

Similar Companies

SurModics & 98 more

View Spear Bio's full profile

Spear Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Spear Bio Inc CIN: 861761044 , United States, Active	Dec 31, 2020	-	-	-

Spear Bio has raised a total funding of $49M over 4 rounds. Its first funding round was on Oct 14, 2021. Its latest funding round was a Series A round on Jul 23, 2024 for $*****. 5 investors participated in its latest round. Spear Bio has 7 institutional investors.

Here is the list of recent funding rounds of Spear Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 23, 2024	2781396	Series A	3614707	4148195	2376471	3359172
Nov 13, 2023	7453925	Seed	5359763	9123604	7592281	Maverick Ventures & 1 more
Oct 18, 2022	8925115	Seed	9340143	7023701	4820282	2582629

Access funding benchmarks and valuations. Sign up today!

View details of Spear Bio's funding rounds and investors

The founders of Spear Bio are Peng Yin and Feng Xuan. Feng Xuan is the CEO of Spear Bio.

Here are the details of Spear Bio's key team members:

Peng Yin: Co-Founder of Spear Bio and founder of 2 other companies, panOpen and NuProbe.
Contact Info: 1 email address
Feng Xuan: Co-Founder & CEO of Spear Bio.

View details of Spear Bio's Founder profiles and Board Members

Spear Bio's employee count trend

Spear Bio has 48 employees as of Feb 26. Here is Spear Bio's employee count trend over the years:

Uncover Spear Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spear Bio include SurModics, Olink and Accellix. Here is the list of Top 10 competitors of Spear Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spear Bio 2021, Boston (United States), Series A	Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers	$49M	Foresite Capital, Maverick Ventures & 5 others	62/100
2nd	SurModics 1979, Eden Prairie (United States), Acquired	Manufacturer of in-vitro diagnostic assays and reagents	-	-	62/100
3rd	Olink 2004, Uppsala (Sweden), Acquired	Provider of products and services for human protein biomarker research and development	-	Vitruvian Partners, Green Sands Equity & 4 others	61/100
4th	Accellix 2007, San Jose (United States), Acquired	Developer of immunotherapy-based assay delivery platform	$35.8M	Axcel, BioMerieux & 2 others	60/100
5th	US BioTek Laboratories 2008, Shoreline (United States), Acquired	Provider of enzyme-linked immunosorbent assay technology services	$19.5M	Capitala Group, Pike Street Capital	58/100
6th	ProAxsis 2013, Belfast (United Kingdom), Acquired	Developer of diagnostic test for the detection of respiratory conditions	$2.79M	Northern Ireland Science, NetScientific & 5 others	48/100
7th	Correlia Biosystems 2013, Berkeley (United States), Series A	Developer of immunoassay platforms to quantify proteins for proteomics and pharmaceutical applications	$10.9M	Neotribe, Cota Capital & 12 others	47/100
8th	RemedyBio 2017, Dublin (Ireland), Series A	Provider of personalised, cell based, autologous and anti-tumour therapy	$9.43M	Enterprise Ireland, EIC Fund & 3 others	46/100
9th	ET Healthcare 2008, Shanghai (China), Series D	Provider of an electrochemiluminescence analyzer	$15.5M	Sequoia Capital China, Kaiser Permanente & 9 others	44/100
10th	Presage Biosciences 2008, Seattle (United States), Series E	Translational oncology company pioneering drug development with its CIVO platform	$35M	Celgene, Takeda Ventures & 6 others	44/100